(Q39640373)

13 September 2017

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice (English)

1 reference

13 September 2017

1 reference

A Maida

1

1 reference

13 September 2017

B J Lamont

series ordinal

2

1 reference

13 September 2017

X Cao

series ordinal

3

1 reference

13 September 2017

D J Drucker

series ordinal

4

1 reference

13 September 2017

23 October 2010

1 reference

13 September 2017

1 reference

13 September 2017

54

1 reference

13 September 2017

2

1 reference

13 September 2017

339-349

1 reference

https://scigraph.springernature.com/pub.10.1007/s00125-010-1937-z

13 September 2017

0 references

cites work

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Mechanism by which metformin reduces glucose production in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Role of KLF15 in regulation of hepatic gluconeogenesis and metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Enhanced secretion of glucagon-like peptide 1 by biguanide compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Identification of molecular target of AMP-activated protein kinase activator by affinity purification and mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Glucose, metformin, and AICAR regulate the expression of G protein-coupled receptor members in INS-1 beta cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Metformin-induced stimulation of AMP-activated protein kinase in beta-cells impairs their glucose responsiveness and can lead to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1937-Z

Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes.

21 January 2018

1 reference

12 December 2020

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

1 reference

12 December 2020

Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum

1 reference

12 December 2020

Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: possible mechanism for the GIP resistance in type

1 reference

12 December 2020

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

1 reference

12 December 2020

Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice

1 reference

12 December 2020

A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells

1 reference

12 December 2020

10.1007/S00125-010-1937-Z

Identifiers

DOI

1 reference

13 September 2017

1 reference